Atea Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AVIR Nasdaq 2834 ateapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atea Pharmaceuticals, Inc.

June 2025's Promising Penny Stocks - Jun 26th, 2025 6:04 am
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America - Jun 24th, 2025 5:00 am
Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Jun 17th, 2025 1:25 pm
Top Penny Stocks To Watch In May 2025 - May 21st, 2025 12:06 pm
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - May 12th, 2025 2:11 pm
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - May 7th, 2025 5:00 am
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - May 1st, 2025 5:00 am
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - Apr 23rd, 2025 5:00 am
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - Apr 17th, 2025 5:00 am
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Apr 9th, 2025 5:00 am
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - Mar 26th, 2025 11:58 am
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Mar 26th, 2025 7:34 am
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Mar 26th, 2025 6:00 am
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - Mar 21st, 2025 3:54 pm
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory - Mar 21st, 2025 6:25 am
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 - Mar 19th, 2025 5:00 am
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Mar 13th, 2025 11:05 am
Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ... - Mar 7th, 2025 12:17 am
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Mar 6th, 2025 2:05 pm
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - Feb 27th, 2025 5:00 am